David Loew swaps Sanofi’s top vaccine job for CEO role at IpsenSanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as Share XDavid Loew swaps Sanofi’s top vaccine job for CEO role at Ipsenhttps://pharmaphorum.com/news/david-loew-swaps-sanofis-top-vaccine-job-for-ceo-role-at-ipsen/
Novartis closes on EU approval for breast cancer drug PiqrayNovartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, Share XNovartis closes on EU approval for breast cancer drug Piqrayhttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-breast-cancer-drug-piqray/
Gilead trumpets data with newly-bought magrolimab in blood cancersJust three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the Share XGilead trumpets data with newly-bought magrolimab in blood cancershttps://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerAfter a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi Share XAZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerhttps://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trialsBristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough Share XCompetition heats up in BCMA CAR-T as J&J, BMS update myeloma trialshttps://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/
Sanofi appoints new chief digital officer in C-Suite revampSanofi’s new CEO Paul Hudson has completed his revamp of the company’s executive committee, including the appointment of Share XSanofi appoints new chief digital officer in C-Suite revamphttps://pharmaphorum.com/news/sanofi-appoints-new-chief-digital-officer-in-management-revamp/
Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
Oxford Biomedica signs COVID-19 vaccine supply deal with AZGene and cell therapy specialist Oxford Biomedica has signed a one-year agreement with AstraZeneca to manufacture the potential COVID-19 vaccine in Share XOxford Biomedica signs COVID-19 vaccine supply deal with AZhttps://pharmaphorum.com/news/oxford-biomedica-signs-covid-19-vaccine-supply-deal-with-az/
Roche signs up with Oncimmune to explore immunotherapy responsesRoche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ Share XRoche signs up with Oncimmune to explore immunotherapy responseshttps://pharmaphorum.com/news/roche-signs-up-with-oncimmune-to-explore-immunotherapy-responses/
GSK to produce a billion doses of COVID-19 vaccine booster by 2021GlaxoSmithKline is to scale up production of its COVID-19 vaccine booster to a billion doses by 2021 to support development of Share XGSK to produce a billion doses of COVID-19 vaccine booster by 2021https://pharmaphorum.com/news/gsk-to-produce-a-billion-doses-of-covid-19-vaccine-booster-by-2021/
PureTech to develop drug to treat lung scarring in COVID-19 patientsUS biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and Share XPureTech to develop drug to treat lung scarring in COVID-19 patientshttps://pharmaphorum.com/news/puretech-to-develop-drug-to-treat-lung-scarring-in-covid-19-patients/
BMS wins another lung cancer approval for its Opdivo+Yervoy comboBristol-Myers Squibb has won another first-line lung cancer approval from the FDA for its Opdivo and Yervoy immunotherapy combination. The big pharma has Share XBMS wins another lung cancer approval for its Opdivo+Yervoy combohttps://pharmaphorum.com/news/bms-wins-another-lung-cancer-approval-for-its-opdivoyervoy-combo/
Artificial intelligence spots COVID-19 in chest X-raysResearchers in the UK say they developed an artificial intelligence-based computer model that can reliably detect COVID-19 in Share XArtificial intelligence spots COVID-19 in chest X-rayshttps://pharmaphorum.com/news/artificial-intelligence-spots-covid-19-from-chest-x-rays/
UK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientsThe UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 Share XUK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientshttps://pharmaphorum.com/news/uk-okays-early-access-to-gileads-remdesivir-in-seriously-ill-covid-19-patients/
Novartis builds case for MS drug ofatumumab as FDA decision loomsNovartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease Share XNovartis builds case for MS drug ofatumumab as FDA decision loomshttps://pharmaphorum.com/news/novartis-builds-case-for-ms-drug-ofatumumab-as-fda-decision-looms/
Collaborative KOL Engagement Plans Share XCollaborative KOL Engagement Planshttps://pharmaphorum.com/partner-content/collaborative-kol-engagement-plans/
Envisagenics presents latest case study at Therapeutics and Delivery Share XEnvisagenics presents latest case study at Therapeutics and Deliveryhttps://pharmaphorum.com/partner-content/envisagenics-presents-latest-case-study-at-therapeutics-and-delivery/
Jace Blackburn, Smart Device Engineer, Genentech presents at PFS Syringes San Francisco Share XJace Blackburn, Smart Device Engineer, Genentech presents at PFS Syringes San Franciscohttps://pharmaphorum.com/partner-content/jace-blackburn-smart-device-engineer-genentech-presents-at-pfs-syringes-san-francisco/
J+D FORECASTING ANNOUNCE AN UPGRADE AND AN EXTENSION Share XJ+D FORECASTING ANNOUNCE AN UPGRADE AND AN EXTENSIONhttps://pharmaphorum.com/partner-content/pharma-forecasting-software-for-greater-efficiency-and-enjoyment/
Prescient hires senior members to Advisory Share XPrescient hires senior members to Advisoryhttps://pharmaphorum.com/partner-content/prescient-hires-senior-members-to-advisory/
Prescient Intelligence & Insight announces recent appointments to the senior team Share XPrescient Intelligence & Insight announces recent appointments to the senior teamhttps://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team/
